These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 19035443)

  • 1. Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas.
    Ashida A; Takata M; Murata H; Kido K; Saida T
    Int J Cancer; 2009 Feb; 124(4):862-8. PubMed ID: 19035443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of KIT expression and gene mutation in human acral melanoma: with a comparison between primary tumors and corresponding metastases/recurrences.
    Dai B; Cai X; Kong YY; Yang F; Shen XX; Wang LW; Kong JC
    Hum Pathol; 2013 Aug; 44(8):1472-8. PubMed ID: 23528861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatic activation of KIT in distinct subtypes of melanoma.
    Curtin JA; Busam K; Pinkel D; Bastian BC
    J Clin Oncol; 2006 Sep; 24(26):4340-6. PubMed ID: 16908931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KIT gene mutations and patterns of protein expression in mucosal and acral melanoma.
    Abu-Abed S; Pennell N; Petrella T; Wright F; Seth A; Hanna W
    J Cutan Med Surg; 2012; 16(2):135-42. PubMed ID: 22513068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: a case report.
    Rapisuwon S; Parks K; Al-Refaie W; Atkins MB
    Melanoma Res; 2014 Oct; 24(5):509-11. PubMed ID: 25003536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma.
    Buchbinder EI; Sosman JA; Lawrence DP; McDermott DF; Ramaiya NH; Van den Abbeele AD; Linette GP; Giobbie-Hurder A; Hodi FS
    Cancer; 2015 Nov; 121(22):4007-15. PubMed ID: 26264378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type.
    Torres-Cabala CA; Wang WL; Trent J; Yang D; Chen S; Galbincea J; Kim KB; Woodman S; Davies M; Plaza JA; Nash JW; Prieto VG; Lazar AJ; Ivan D
    Mod Pathol; 2009 Nov; 22(11):1446-56. PubMed ID: 19718013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
    Hodi FS; Corless CL; Giobbie-Hurder A; Fletcher JA; Zhu M; Marino-Enriquez A; Friedlander P; Gonzalez R; Weber JS; Gajewski TF; O'Day SJ; Kim KB; Lawrence D; Flaherty KT; Luke JJ; Collichio FA; Ernstoff MS; Heinrich MC; Beadling C; Zukotynski KA; Yap JT; Van den Abbeele AD; Demetri GD; Fisher DE
    J Clin Oncol; 2013 Sep; 31(26):3182-90. PubMed ID: 23775962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential.
    Huang S; Luca M; Gutman M; McConkey DJ; Langley KE; Lyman SD; Bar-Eli M
    Oncogene; 1996 Dec; 13(11):2339-47. PubMed ID: 8957075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate.
    Hofmann UB; Kauczok-Vetter CS; Houben R; Becker JC
    Clin Cancer Res; 2009 Jan; 15(1):324-9. PubMed ID: 19118061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition.
    Antonescu CR; Busam KJ; Francone TD; Wong GC; Guo T; Agaram NP; Besmer P; Jungbluth A; Gimbel M; Chen CT; Veach D; Clarkson BD; Paty PB; Weiser MR
    Int J Cancer; 2007 Jul; 121(2):257-64. PubMed ID: 17372901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KIT amplification and gene mutations in acral/mucosal melanoma in Korea.
    Yun J; Lee J; Jang J; Lee EJ; Jang KT; Kim JH; Kim KM
    APMIS; 2011 Jun; 119(6):330-5. PubMed ID: 21569090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sunitinib therapy for melanoma patients with KIT mutations.
    Minor DR; Kashani-Sabet M; Garrido M; O'Day SJ; Hamid O; Bastian BC
    Clin Cancer Res; 2012 Mar; 18(5):1457-63. PubMed ID: 22261812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature.
    Satzger I; Küttler U; Völker B; Schenck F; Kapp A; Gutzmer R
    Dermatology; 2010; 220(1):77-81. PubMed ID: 19996579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KIT pathway alterations in mucosal melanomas of the vulva and other sites.
    Omholt K; Grafström E; Kanter-Lewensohn L; Hansson J; Ragnarsson-Olding BK
    Clin Cancer Res; 2011 Jun; 17(12):3933-42. PubMed ID: 21680547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Large-scale analysis of KIT aberrations in Chinese patients with melanoma.
    Kong Y; Si L; Zhu Y; Xu X; Corless CL; Flaherty KT; Li L; Li H; Sheng X; Cui C; Chi Z; Li S; Han M; Mao L; Lu A; Guo J
    Clin Cancer Res; 2011 Apr; 17(7):1684-91. PubMed ID: 21325067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure.
    Handolias D; Salemi R; Murray W; Tan A; Liu W; Viros A; Dobrovic A; Kelly J; McArthur GA
    Pigment Cell Melanoma Res; 2010 Apr; 23(2):210-5. PubMed ID: 20088873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis.
    Steeb T; Wessely A; Petzold A; Kohl C; Erdmann M; Berking C; Heppt MV
    Eur J Cancer; 2021 Nov; 157():348-357. PubMed ID: 34562816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KIT gene mutations and copy number in melanoma subtypes.
    Beadling C; Jacobson-Dunlop E; Hodi FS; Le C; Warrick A; Patterson J; Town A; Harlow A; Cruz F; Azar S; Rubin BP; Muller S; West R; Heinrich MC; Corless CL
    Clin Cancer Res; 2008 Nov; 14(21):6821-8. PubMed ID: 18980976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of correlation between immunohistochemical expression of CKIT and KIT mutations in atypical acral nevi.
    Park E; Yang S; Emley A; DeCarlo K; Richards J; Mahalingam M
    Am J Dermatopathol; 2012 Feb; 34(1):41-6. PubMed ID: 22094233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.